The dysfunction in how Australia and New Zealand approach pharmaceutical reimbursement is not just procedural. It is rooted in how these systems think about themselves and the myths that sustain their authority. For years, debates over these programs have been channelled into technical terrain that the institution controls and comfortably defends. Institutions shield themselves through their own mythology, recasting policy choices as unquestionable truths. Real reform depends on challenging those myths and exposing the political decisions they conceal.
Process as power - how our institutions defend policy decisions by making them untouchable truths
October 30, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News

